验证数据展示
经过测试的应用
| Positive FC detected in | human PBMCs | 
推荐稀释比
| 应用 | 推荐稀释比 | 
|---|---|
| Flow Cytometry (FC) | FC : 5 ul per 10^6 cells in 100 μl suspension | 
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
CL405-98013 targets Endoglin/CD105 in FC applications and shows reactivity with human samples.
| 经测试应用 | FC Application Description | 
| 经测试反应性 | human | 
| 免疫原 | 
                                             Recombinant protein 种属同源性预测 | 
                                    
| 宿主/亚型 | Rabbit / IgG | 
| 抗体类别 | Recombinant | 
| 产品类型 | Antibody | 
| 全称 | endoglin | 
| 别名 | CD105, 230047E5, HHT1, ENG, Endoglin | 
| 计算分子量 | 71 kDa | 
| GenBank蛋白编号 | BC014271 | 
| 基因名称 | CD105 | 
| Gene ID (NCBI) | 2022 | 
| RRID | AB_3672408 | 
| 偶联类型 | CoraLite® Plus 405 Fluorescent Dye | 
| 最大激发/发射波长 | 399 nm / 422 nm | 
| 形式 | Liquid | 
| 纯化方式 | Protein A purification | 
| UNIPROT ID | P17813 | 
| 储存缓冲液 | PBS with 0.09% sodium azide and 0.5% BSA, pH 7.3. | 
| 储存条件 | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. | 
背景介绍
Endoglin (ENG, CD105) is a homodimeric cell membrane glycoprotein of 180 kDa, composed of disulphide-linked subunits of 90-95 kDa. Endoglin is a proliferation-associated and hypoxia-inducible protein mainly expressed on vascular endothelial cells. It acts as an accessory receptor for transforming growth factor beta (TFG-β) and is involved in vascular development and remodeling. The important role of Endoglin in angiogenesis and in tumor progression makes it an ideal target for antiangiogenic therapy and a good marker for tumor prognosis. (PMID: 1326540; 14528280; 21737653; 12773481)
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for CL Plus 405 Endoglin/CD105 antibody CL405-98013 | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 

